Document is current

Article History

Received: 4 May 2022

Accepted: 31 August 2022

First Online: 24 September 2022

Declarations

:

: The ethics committee of the Medical Association of Rhineland Palatinate, Mainz, Germany, approved this study (permit number 837.199.10). The requirement for informed consent was waived for the retrospective analysis of clinical data.

: Not applicable.

: RK reports personal fees from Boston Scientific, personal fees from Bristol-Myers Squibb, personal fees from Guerbet, personal fees from SIRTEX, personal fees from Roche, personal fees from BTG, personal fees from Ipsen, personal fees from Siemens, personal fees from MSD - Merck Sharp & Dohme. FF reports receiving consulting and lectures fees from Roche; lectures fees from Lilly and Pfizer. AW received compensations as a member of scientific advisory boards for Bayer, BMS, Eisai, and Sanofi and served as a speaker for Leo Pharma, Eisai, Ipsen, and Roche and received travel support from Merck and Servier. PRG reports receiving consulting and lectures fees from Adaptimmune, AstraZeneca, Bayer, BMS, Boston Scientific, Eisai, Guerbet, Ipsen, Lilly, MSD, Roche, Sirtex. None of these influenced the conduction of this study. None of the other authors reports a conflict of interest.